Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
4.9600
-0.0400 (-0.80%)
NASDAQ · Last Trade: Nov 5th, 4:45 PM EST
Recursion's Q3 2025 results show a major revenue miss and widening loss, but the company highlights strong partnerships and a cash runway into 2027.
Via Chartmill · November 5, 2025
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
Via TokenRing AI · November 4, 2025
Can this under-the-radar stock be a great way to cash in on AI?
Via The Motley Fool · November 4, 2025
Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Sharesfool.com
Via The Motley Fool · October 20, 2025
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by industry observers like PharmTech.com, rapid workforce upskilling is no longer a luxury but a critical necessity for companies aiming to thrive in this new era. The immediate significance [...]
Via TokenRing AI · October 31, 2025
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to market. Driven by advanced data integration and sophisticated analytics, AI is dramatically accelerating timelines, reducing costs, and significantly improving success rates across the entire drug development pipeline. This paradigm [...]
Via TokenRing AI · October 31, 2025
Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.
Via The Motley Fool · October 31, 2025
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift towards personalized medicine. Artificial intelligence (AI) stands at the forefront of this revolution, offering unprecedented capabilities to overcome long-standing challenges and accelerate the delivery of tailored, effective treatments. [...]
Via TokenRing AI · October 22, 2025
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat.
Via Benzinga · October 22, 2025
The U.S. stock market has staged a remarkable recovery in October 2025, with major indices reclaiming lost ground amidst a confluence of positive corporate earnings and improving macroeconomic sentiment. However, a significant driver behind this upward trajectory isn't just institutional buying; it's a dramatic surge in heavily-shorted stocks, igniting
Via MarketMinute · October 21, 2025
It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger.
Via The Motley Fool · October 21, 2025
Via Benzinga · October 20, 2025
Not every promising prospect is currently priced too richly relative to its risk.
Via The Motley Fool · October 19, 2025
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · October 16, 2025
This is the only biotech stock to attract an investment from artificial intelligence (AI) giant Nvidia.
Via The Motley Fool · October 16, 2025
Via Benzinga · October 15, 2025
The pharmaceutical industry stands on the precipice of a revolutionary transformation, driven by the burgeoning power of artificial intelligence (AI) agents. These sophisticated, autonomous systems are rapidly redefining the drug discovery process, moving beyond mere data analysis to actively generating hypotheses, designing novel molecules, and orchestrating complex experimental workflows. As of October 2025, AI agents [...]
Via TokenRing AI · October 14, 2025
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to market. By combining generative artificial intelligence with high-throughput wet lab technologies, Absci aims to drastically cut down the time and cost associated
Via MarketMinute · October 13, 2025
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?
Via MarketBeat · October 13, 2025
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Via The Motley Fool · October 12, 2025
On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&P 500 slipping nearly 0.6% to 6,753.72. The Dow Jones Industrial Average was unchanged at 46,601.78.These are the top stocks that gained the attention of retail traders and investors through the day:
Via Benzinga · October 8, 2025
Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 and extended cash runway.
Via Benzinga · October 8, 2025